icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
DXeDN6kPd6e7F3nJ
Listen
